New EU guidance for the evaluation of medicinal products with modified drug release will be finished by the middle of 2014
Journal Title: Generics and Biosimilars Initiative Journal - Year 2014, Vol 3, Issue 2
Abstract
The guideline ‘Note for guidance on modified release oral and transdermal dosage forms: Section II (Pharmacokinetic and clinical evaluation)’ [1] was issued over 10 years ago, and the need for revision was recognized in 2010. An international group of experts, led by Austrian members of the Pharmacokinetics Working Party, is responsible for its implementation. They have joined forces with the Quality Working Party, which revises guidelines on the quality of such products, and various other expert groups of the European Medicines Agency (EMA). A draft version was recently produced and approval obtained from EMA’s Committee for Medicinal Products for Human Use; it was then posted on the EMA website for feedback [2].
Authors and Affiliations
Christoph Baumgärtel, Jan Neuhauser
Keywords
Related Articles
- EP ID EP354465
- DOI 10.5639/gabij.2014.0302.024
- Views 76
- Downloads 0
Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach
Introduction: Pharmaceutical expenditure continues to rise driven by a number of factors including ageing populations and the continued launch of new premium-priced drugs. Increasing use of generics versus originators an...
Oncologists urged to embrace biosimilars to help control spiralling costs of cancer care
Oncologists urged to embrace biosimilars to help control spiralling costs of cancer care Oncologists have been urged to embrace biosimilar drug substitution to help control the spiralling costs of cancer care. However, t...
Statin generics: no differences in efficacy after switching
A study presented at the 2010 Congress of the European Society of Cardiology, had created a considerable stir. Its abstract allegedly showed that the originator drug Lipitor was more beneficial than any of its generic st...
GaBI Journal publishes four issues in 2013
This issue marks the forth and final issue of the second year’s edition of the GaBI Journal. The journal has grown rapidly through the combined efforts of the publisher and her staff, all of the members of the executive...
Equivalence of generic medicines in general and immunosuppressants in particular – a regulatory opinion on switching of ciclosporin, tacrolimus and mycophenolate mofetil
This position paper deals with our regulatory opinion on registered generic immunosuppressants such as ciclosporin, tacrolimus and mycophenolate mofetil, and provides arguments why these medicines are considered equally...